Saturday, March 2, 2024

UK begins major trial for new inhaler-based COVID treatment

Date:

Share post:

spot_img

London, Jan 13: A new potentially life-saving inhaler-based treatment which is hoped will protect COVID-19 patients from developing severe illness has begun a major trial at UK hospitals. It involves inhaling a protein called interferon beta-1a (SNG001), which the body produces when it gets a viral infection, and the hope is it will stimulate the body’s immune system and prime cells to be ready to fight off viruses.
Synairgen’s SG018 trial is a randomised placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen. “We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2 [COVID-19]. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective,” said Richard Marsden, CEO of Synairgen.
“We believe this trial presents an opportunity for a significant UK scientific breakthrough and if given the right support, our drug could rapidly assist with the global crisis,” he said.
After reporting the results for the primary and key secondary endpoints of the study, enrolled patients will continue to be assessed for long-COVID-19 symptoms. Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic.
It has appointed Parexel Biotech, a division of the leading global clinical research organisation Parexel to help conduct the Phase III trial and several UK sites have now been initiated, with further sites in the US and the European Union (EU) expected to follow. Early findings suggested the treatment cut the odds of a COVID-19 patient in hospital developing severe disease, such as requiring ventilation, by almost 80 per cent.
The results of a smaller, phase two clinical trial of the treatment conducted last year suggested the chances of a COVID-19 patient in the hospital getting the severe disease – requiring ventilation, for example – were reduced. Patients were two to three times more likely to recover to the point where everyday activities were not compromised by their illness, Synairgen claimed.
The large-scale trial is deemed an Urgent Public Health study by the UK’s National Institute for Health Research (NIHR).
In the US, SNG001 has been granted fast-Track status from the US Food and Drug Administration (FDA). (PTI)

spot_img

Related articles

All-faith forum seeks sanity on troubled border

By Our Reporter SHILLONG, March 1: The Shillong All Faith Forum (SAFF) on Friday asked the Assam and Meghalaya...

State govt seeks national status for NEIGRIHMS

By Our Reporter SHILLONG, March 1: The state government has urged Union Health Minister Mansukh Mandaviya to designate NEIGRIHMS...

Smooth start to HSSLC exams; SSLC from Monday

By Our Reporter SHILLONG, March 1: The Higher Secondary School Leaving Certificate (HSSLC) examinations conducted by the Meghalaya Board...

Govt to seek more MBBS seats from central pool

By Our Reporter SHILLONG, March 1: The state government is contemplating to send a proposal to the Centre to...